DuPont Pharma Has "A Number Of Bidders"; Company Still Considering IPO
Executive Summary
DuPont has had several companies express interest in purchasing its pharmaceutical business, DuPont Pharmaceuticals Chairman Richard DeSchutter told an April 11 meeting with securities analysts.
You may also be interested in...
DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II
DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.
DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II
DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.
DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears
DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.